Soligenix announced that patient enrollment has been opened for the investigator-initiated study at the University of Pennsylvania, supported by a $2.6M Orphan Products Development grant award by the FDA. The IIS will evaluate the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T-cell lymphoma.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNGX: